Caliway Biopharmaceuticals Co (TPE:6919) Payments of Debt: NT$0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6919 Caliway Biopharmaceuticals Co Ltd TPE:6919
55 GF Score
Price NT$99.60
GF Value NT$59.00
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Caliway Biopharmaceuticals Co Payments of Debt?

Caliway Biopharmaceuticals Co TPE:6919 -3.30% 55 Payments of Debt is NT$0.00 Mil as of Jun. 2026. GuruFocus rates TPE:6919 with a GF Score™ of 55/100 and a GF Value™ of NT$59.00 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Caliway Biopharmaceuticals Co's Payments of Debt for the three months ended in Jun. 2026 was NT$0.00 Mil.

Caliway Biopharmaceuticals Co's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.00 Mil.

Caliway Biopharmaceuticals Co Payments of Debt Related Terms

Caliway Biopharmaceuticals Co Payments of Debt Historical Data

* Premium members only.

The historical data trend for Caliway Biopharmaceuticals Co's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caliway Biopharmaceuticals Co Payments of Debt Chart

Caliway Biopharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial -87.19 -4.72 0.00 0.00 0.00

Caliway Biopharmaceuticals Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:6919
55GF Score
Caliway Biopharmaceuticals Co Ltd TPE:6919
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caliway Biopharmaceuticals Co Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of NT$0.00 Mil mean?
Caliway Biopharmaceuticals Co (TPE:6919) has a Payments of Debt of NT$0.00 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Caliway Biopharmaceuticals Co and its competitors.
Is Caliway Biopharmaceuticals Co's Payments of Debt too high?
Caliway Biopharmaceuticals Co's current Payments of Debt is NT$0.00 Mil. Overall, Caliway Biopharmaceuticals Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caliway Biopharmaceuticals Co's Payments of Debt compare to VRTX and REGN?
Caliway Biopharmaceuticals Co's Payments of Debt of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Caliway Biopharmaceuticals Co and its competitors. Caliway Biopharmaceuticals Co's current Payments of Debt is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliway Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co (TPE:6919) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$59.00, compared to a current price of NT$99.60 — trading 68.8% above its estimated fair value. The current Payments of Debt is NT$0.00 Mil. Caliway Biopharmaceuticals Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Caliway Biopharmaceuticals Co (TPE:6919), the current Payments of Debt is NT$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caliway Biopharmaceuticals Co (TPE:6919) Overvalued in 2026?

Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co stock appears to be overvalued. The current stock price of NT$99.60 is trading 68.8% above its estimated GF Value™ of NT$59.00. GuruFocus considers Caliway Biopharmaceuticals Co to be Significantly Overvalued.

Key valuation signals for TPE:6919:

  • Payments of Debt: NT$0.00 Mil
  • GF Value™: NT$59.00 vs. price of NT$99.60 (68.8% above fair value)
  • GF Score™: 55/100 with 8 warning signs

No single metric tells the full story. See the TPE:6919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caliway Biopharmaceuticals Co Business Description

Address No.99, Section 1, Xintai 5th Road, 32rd Floor-9, Xizhi District, New Taipei City, TWN, 221
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
55GF Score

Get the complete analysis for TPE:6919

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$99.60
Price
NT$59.00
GF Value